Clinical trials
Metastatic Prostate Adenocarcinoma clinical trials
Below are recruiting metastatic prostate adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 246 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05168618RecruitingPhase 2
Cabozantinib and atezolizumab for advanced prostate cancer
This Phase 2 trial tests cabozantinib plus atezolizumab in people with metastatic prostate cancer that keeps growing despite hormone-blocking therapy and newer hormone drugs. It may help shrink tumors and control the disease, especially in advanced cases where options are limited.
Salt Lake City, UtahAges 18 years+ - NCT05352178RecruitingPhase 3
Targeted treatment for few-spread prostate cancer spots
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
LeuvenAges 18 years+ - NCT05691465RecruitingPhase 2
Radiation drug for metastatic prostate cancer with neuroendocrine cells
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Duarte, CaliforniaAges 18 years+ - NCT05720130RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer found on PSMA scans
This trial tests [212Pb]Pb-ADVC001, a radiotherapy-like cancer treatment, in people with advanced prostate cancer that shows up on a special PSMA scan. It aims to find the safest dose and see whether it helps shrink or control metastatic cancer.
Brisbane, QueenslandAges 18 years+ - NCT05796973RecruitingPhase 3
Exercise and atorvastatin for metastatic cancer outcomes
This trial tests whether a structured exercise program, along with the cholesterol medicine atorvastatin, can improve outcomes in people with metastatic prostate, breast, ovarian, or kidney cancer. It may help by reducing inflammation and supporting physical function during cancer treatment.
Tampere, Länsi-SuomiAges 18–99 - NCT05800665RecruitingPhase 1
Study tests a new prostate cancer drug after prior hormone therapy
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
Scottsdale, ArizonaAges 18 years+ - NCT06141993Recruiting
Study of blood markers in hormone therapy resistance for prostate cancer
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
New York, New YorkAges 18 years+ - NCT06145633RecruitingPhase 2
Vorinostat and 177Lu-PSMA-617 for PSMA-Low prostate cancer
This trial tests two drugs: vorinostat (a pill that may make cancer cells easier to target) and 177Lu-PSMA-617 (a radioactive drug that seeks out prostate cancer cells). It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and shows low levels of PSMA on a PET scan.
Seattle, WashingtonAges Any age - NCT06205316RecruitingPhase 3
Radiation therapy for returning or limited-spread prostate cancer
This trial compares two types of radiation therapy for prostate cancer that has come back or spread to a few places after surgery. The goal is to see which radiation schedule works better with fewer side effects.
Scottsdale, ArizonaAges 18 years+ - NCT04945642Recruiting
Radiation combination therapy for intermediate to high-risk prostate cancer
This trial studies a combination of two radiation types—high-dose-rate brachytherapy and stereotactic body radiotherapy—to treat certain intermediate- to high-risk prostate cancers. It may help by aiming radiation closely at the prostate while also targeting the cancer from outside the body.
Los Angeles, CaliforniaAges 18 years+ - NCT06616155RecruitingPhase 1/Phase 2
Ruxolitinib and Enzalutamide for Resistant Prostate Cancer
This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.
Chicago, IllinoisAges 18 years+ - NCT06616597RecruitingPhase 2
Targeting gut bacteria to help prostate cancer treatment work again
This trial tests whether adding metronidazole, an antibiotic, can make abiraterone work better in men with metastatic prostate cancer whose PSA is rising despite treatment. It aims to target gut bacteria that may be fueling resistance to the therapy.
Baltimore, MarylandAges 18 years+ - NCT06854250RecruitingPhase 2
Cryoablation and low-dose chemo for metastatic prostate cancer
This trial tests freezing prostate tumors (cryoablation) combined with a low-dose chemotherapy pill (metronomic cyclophosphamide) for men with metastatic prostate cancer. The goal is to see if this combination can slow the cancer's growth and improve outcomes.
Guangzhou, GuangdongAges 18–80 - NCT06957691RecruitingPhase 2
Fezolinetant for hot flashes in men on hormone therapy
This study tests whether a medication called fezolinetant can reduce hot flashes in men with prostate cancer caused by hormone therapy (ADT). If you have frequent, bothersome hot flashes, this treatment may help.
Boston, MassachusettsAges 40 years+ - NCT07038304RecruitingPhase 2
Radiation for cancer growth in prostate cancer that stopped responding to hormones
This trial tests whether giving precise radiation to a few spots of cancer growth can help control prostate cancer that has stopped responding to hormone therapy. It is for people with up to 3 growing or new spots of cancer on a special scan.
GroningenAges 18 years+ - NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Chicago, IllinoisAges 18 years+ - NCT07179783RecruitingPhase 2
Sacituzumab Tirumotecan and Tagitanlimab for aggressive prostate cancer
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07219147RecruitingPhase 1
Combination treatment for advanced prostate cancer
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07284277RecruitingPhase 1/Phase 2
TTFields and chemo for metastatic pancreatic cancer
This trial tests a wearable device (TTFields) combined with a specific chemotherapy (mFOLFIRINOX) for people whose pancreatic cancer has spread to the liver and other organs. The device sends gentle electrical fields to disrupt cancer cell growth, and the chemo attacks cancer cells throughout the body.
Pamplona, NavarreAges 18 years+ - NCT07339267RecruitingPhase 1
Safety and dosing study of ASP5541 in Chinese men with metastatic prostate cancer
This study tests a new drug called ASP5541 for Chinese men with prostate cancer that has spread. The drug is given as a shot, and researchers want to see if it is safe and what the right dose might be.
Beijing, Beijing MunicipalityAges 18–85 - NCT07407608Recruiting
Radiation therapy for unfavorable prostate cancer
This trial tests a type of focused radiation therapy for men with intermediate or high-risk prostate cancer that hasn't spread. It aims to improve outcomes by targeting the main tumor seen on MRI.
Monza, MBAges 18–90 - NCT07414940RecruitingPhase 1/Phase 2
Actinium-225 PSMA for advanced prostate cancer after Lu-177
This trial tests a new targeted radiation drug called actinium-225 PSMA for men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Lu-177 PSMA (a similar targeted radiation therapy). It aims to see if this stronger radiation can help when the first type stops working.
LondonAges 18 years+ - NCT07484971Recruiting
Prostate cancer study in Algeria
This study looks at how prostate cancer is found and treated in Algeria. The goal is to learn more about the disease to improve care for future patients.
Adrar, AlgeriaAges 19 years+ - NCT07641049RecruitingPhase 1
CAR-NK Cell Therapy for Advanced Prostate Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
Shenzhen, GuangdongAges 18 years+
Hear when a new Metastatic Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic prostate adenocarcinoma?
- Yes. Clin2 currently lists 246 recruiting metastatic prostate adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic prostate adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic prostate adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.